Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Latanoprostene bunod - Bausch & Lomb/NicOx

Drug Profile

Latanoprostene bunod - Bausch & Lomb/NicOx

Alternative Names: BOL-303259-X; NCX-116; PF-03187207; PF-3187207; Vesneo; VYZULTA

Latest Information Update: 08 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NicOx
  • Developer Bausch & Lomb
  • Class Antiglaucomas; Nitro compounds; Prostaglandins; Small molecules
  • Mechanism of Action Nitric oxide donors; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 04 Jan 2019 Registered for Glaucoma in Canada (Ophthalmic)
  • 04 Jan 2019 Registered for Ocular hypertension in Canada (Ophthalmic)
  • 27 Dec 2018 Bausch & Lomb received the Notice of Compliance from the Health Canada for latanoprostene bunod
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top